Navigation Links
Researchers Identify Novel Mechanism That Make Cancer Tumors Grow
Date:2/10/2009

Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors.

LOS ANGELES, Feb. 10 /PRNewswire-USNewswire/ -- IMBCR researchers uncovered a new way that cancers orchestrate the production of their own blood supply. Recent studies have shown that many tumors make a protein called pleiotrophin (PTN). They now show that PTN produced by tumor cells in multiple myeloma, a common form of bone marrow-based cancer, changes white cells in the blood called "monocytes" into cells that form the lining of blood vessels called "vascular endothelial cells" (VEC). These VEC cells then become incorporated into the blood vessels that form within tumors.

"This is exciting news, and we feel this will not only have a tremendous impact on hematological tumors, such as myeloma, but other cancers as well," said James R. Berenson, M.D., Medical and Scientific Director of the IMBCR. "By uncovering this unique mechanism, how PTN produced by cancers actually changes circulating white cells into cells that line blood vessels that feed the tumor, we can direct our efforts to create more targeted approaches to eliminate blood supplies for cancers which should dramatically improve therapies for many types of cancers."

Haiming Chen, M.D., Ph.D. is the first author of the research, published this week on the cover of BLOOD. Drs. Berenson and Chen collaborated with scientists at Hemaquest, the Scripps Research Institute, Department of Molecular and Experimental Medicine and Cell Biology at Cedars-Sinai Medical Center, Departments of Neurosurgery, Pathology, and Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California at Los Angeles.

Part of IMBCR's multi-year research project, "Cure Myeloma Project," this research was funded by grants from the Skirball and Annenberg Foundations, Kramer Family Foundation and the Myeloma Research Fund.

About IMBCR

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.

IMBCR research has been published in most major oncology journals; Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology. www.imbcr.org


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve ... decision process. As a result, labels need to deliver simple, transparent and clear ...
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading provider of ... has named the company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS ... organizations simply and proactively address potential cybersecurity threats before they happen. The ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a ... in building collagen and elastin in their face, neck, and body through a ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an ... a standard feature on its secure clinical communication platform. The platform allows clinicians ... depending on the type and urgency of a situation. , “We know ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: